PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN
Therapeutic methods are disclosed herein.
1 . A method comprising administering a cyclosporin, an analog or derivative thereof, or a combination thereof, to an eye of a mammal in combination with administration of a therapeutically active agent to said mammal, said therapeutically active agent being a chemotherapy agent, an antiviral agent or an immunomodulator, wherein said method is effective in treating air ocular condition associated with the use of said therapeutically active agent.
2 . The method of claim 1 wherein said cyclosporin is cyclosporin A.
3 . The method of claim 2 wherein said therapeutically active agent is a chemotherapy agent.
4 . The method of claim 2 wherein said therapeutically active agent is an antiviral agent.
5 . The method of claim 2 wherein said therapeutically active agent is an immunomodulator.
6 . The method of claim 2 wherein said ocular condition is nasolacrimal stenosis, chemotherapy induced ocular toxicity, lacrimal duct stenosis, punctal stenosis, lacrimation, abnormal lacrimation, increased tearing, nasolacrimal blockage, keratitis, keratoconjunctivitis, conjunctivitis, or a combination thereof.
7 . The method of claim 3 wherein the therapeutically active agent is docetaxel or fluorouracil.
8 . The method of claim 7 wherein the therapeutically active agent is docetaxel.
9 . The method o claim 8 wherein said ocular condition is nasolacrimal stenosis.
10 . The method of claim 8 wherein said ocular condition is chemotherapy induced ocular toxicity.
11 . The method of claim 8 wherein said ocular condition is lacrimal duct stenosis.
12 . The method of claim 8 wherein said ocular condition is punctal stenosis.
13 . The method of claim 8 wherein said ocular condition is lacrimation.
14 . The method of claim 8 wherein said ocular condition is abnormal lacrimation.
15 . The method of claim 8 wherein said ocular condition is increased tearing.
16 . The method of claim 8 wherein said ocular condition is nasolacrimal blockage.
17 . The method of claim 8 wherein said ocular condition is keratitis.
18 . The method of claim 8 wherein said ocular condition is keratoconjunctivitis.
19 . The method of claim 8 wherein said ocular condition is conjunctivitis.
20 . A method comprising administering cyclosporin A topically to the eye of a person, wherein docetaxel is also administered to said person, wherein said method is effective in treating an ocular condition associated with the administration of docetaxel.